Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates

Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) has scheduled two important investor events. The company will host an investor webcast on August 14, 2025, at 8:30 AM ET to discuss Q2 2025 financial results and provide corporate updates, coinciding with their 10-Q filing. Additionally, CEO Lisa Conte will present at the Emerging Growth Conference on August 20, 2025, from 2:55-3:05 PM ET to discuss near-term catalysts.

Both events will be accessible online, with the Emerging Growth Conference presentation being archived for later viewing on EmergingGrowth.com and their YouTube channel.

Click here to register

Company plans to file its Earnings Report on August 14, 2025 on Form 10-Q for the quarter ended June 30, 2025

Jaguar CEO Lisa Conte presenting August 20 at Emerging Growth Conference to provide updates on near-term catalysts; Click here to register

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / August 12, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Thursday, August 14, 2025, at 8:30 a.m. Eastern to review second-quarter 2025 financials and provide corporate updates.

Participation Instructions for Jaguar Investor Webcast

When: Thursday, August 14, 2025 at 8:30 AM Eastern Time

Participant Registration & Access Link: Click Here

Participation Instructions for Jaguar's Virtual Presentation at the Emerging Growth Conference

When: Wednesday, August 20, 2025 from 2:55 - 3:05 PM Eastern Time

Where: Online (Click Here)

Registration link for conference: Click Here

Replay: An archived webcast of the presentation will be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi^® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Canalevia-CA1, visit canalevia.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that Jaguar will file its 10-Q on August 14, 2025 for the quarter ended June 30, 2025, the expectation that Jaguar will hold an investor webcast on August 14, 2025, and Jaguar's expectation that Jaguar management will present at the August 2025 Emerging Growth Conference. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

hello@jaguar.health

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

FAQ

When will Jaguar Health (JAGX) report Q2 2025 earnings?

Jaguar Health will report Q2 2025 earnings on Thursday, August 14, 2025, with the 10-Q filing and an investor webcast at 8:30 AM Eastern Time.

How can investors access Jaguar Health's Q2 2025 earnings webcast?

Investors can access the webcast by registering through the participant registration and access link provided by the company for the August 14, 2025, 8:30 AM ET event.

When is CEO Lisa Conte presenting at the Emerging Growth Conference?

CEO Lisa Conte will present at the Emerging Growth Conference on Wednesday, August 20, 2025, from 2:55 to 3:05 PM Eastern Time.

Where can investors watch the replay of Jaguar Health's Emerging Growth Conference presentation?

The presentation replay will be available on EmergingGrowth.com and the Emerging Growth YouTube Channel.